Evidence map›Paper›PMID 35830265›Full record

ArticleAmerican journal of respiratory and critical care medicine2022

Evolution of the Gain-of-Function

David A Schwartz, Rachel Z Blumhagen, Tasha E Fingerlin

Abstract readEditorialComment
In one paragraph

Article in American journal of respiratory and critical care medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Journal of clinical medicine · 2024
    Article
  4. Review
4 · The record

Corrections and comments

  • Comment on
    A2022
5 · Who and what money

Authors and funding

3 authors.

David A SchwartzDepartment of Medicine.ORCID 0000-0001-6743-8443
Rachel Z BlumhagenCenter for Genes, Environment and Health National Jewish Health Denver, Colorado.
Tasha E FingerlinCenter for Genes, Environment and Health National Jewish Health Denver, Colorado.

Funding

Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUH3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2022 to 2025
$4.3M
Molecular Determinants of Usual Interstitial Pneumonia (UIP)R01HL158668 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz, Ivana V Yang · 2022 to 2026
$3.5M
Genes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0M
Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUG3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2020 to 2021
$1.7M
BLRD VA I01 BX005295NHLBI NIH HHS R01 HL149836NHLBI NIH HHS R01 HL158668NHLBI NIH HHS UG3 HL151865NHLBI NIH HHS UH3 HL151865
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Gain of Function MutationHospitalizationHumansMucin-5BPolymorphism, GeneticPromoter Regions, GeneticMUC5B protein, humanMucin-5B

Identifiers

PMID35830265
PMCPMC9746841

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.